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Background: HMG-CoA reductase inhibitors or statins lower LDL and reduce mortality from coronary disease. Statins may also possess other 
pleiotropic effects. We previously showed that therapy with rosuvastatin (ROSUVA) in dogs with heart failure (HF) prevents progressive LV dysfunction and 
dilation. This study examined the effects of ROSUVA on the expression of pro-hypertrophy and pro-inflammatory proteins in LV myocardium of HF dogs.
Methods: LV tissue was obtained from dogs with moderate HF (LV ejection fraction 30%-40%) randomized to 3 months therapy with low dose (LD) 
ROSUVA (0.5 mg/kg once daily, n=7), high dose (HD) ROSUVA (3.0 mg/kg once daily, n=7) or to no therapy (Control, n=7). LV tissue from 7 normal 
(NL) dogs was used for comparison. Expression of the hypertrophic mediators NGFI-A binding protein 1 (Nab1), phosphatase and tensin homolog 
(PTEN), phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) and the proinflammatory cytokines interleukin-6 (IL-6) and 
tumor necrosis factor-alpha (TNF) were measured by Western blotting and quantified in densitometric units.
Results: Expression of Nab1, PTEN, PI3K, mTOR, IL-6 and TNF significantly increased in HF Controls compared to NL. ROSUVA significantly 
decreased expression of all the proteins to near NL levels.
Conclusions: In dogs with HF, therapy with ROSUVA normalizes expression of pro-hypertrophic and pro-inflammatory proteins. These findings 
support the benefits of statin therapy that extend beyond LDL lowering.
Protein Expression in Densitometric Units
NL HF-Controls HF+LD RSV HF+HD RSV
Nab1 2521 ± 40 3154 ± 116* 3368 ± 148* 2807 ± 59†^
PTEN 896 ± 101 1692 ± 104* 1350 ±43 *† 1074 ± 54†^
PI3K 2474 ± 94 3289 ± 59* 2722 ± 85*† 2284 ± 61†^
mTOR 12276 ± 434 16414 ± 751* 11731 ± 715† 10827 ± 662†
IL-6 206 ± 4 307 ± 20* 222 ± 9† 227 ± 10†
TNF 116 ± 12 278 ± 24* 245 ± 17* 165 ± 18†^
* = P<0.05 vs. NL; † = P<0.05 vs. HF-Control; ^ = P<0.05 vs. LD
